Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Medtronic
Colorcon
Dow
Johnson and Johnson

Last Updated: May 25, 2022

CLINICAL TRIALS PROFILE FOR ELIDEL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Elidel

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00117377 ↗ Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis Completed Novartis Phase 4 2004-04-01 The purpose of this study is to identify how pimecrolimus cream 1% modifies the molecular and cellular changes associated with the post-lesional phase of atopic dermatitis (AD). Healthy volunteers and patients with atopic dermatitis will be studied.
NCT00119158 ↗ Combination Therapy for Atopic Dermatitis Completed Novartis Pharmaceuticals Phase 4 2004-10-01 Atopic dermatitis is a chronic relapsing disease with acute flares. The standard therapy is to treat acute flares using topical medications. The two most common classes of topical medications for atopic dermatitis (AD) are topical corticosteroids and topical calcineurin inhibitors. Pimecrolimus and topical corticosteroids exert their activity by different mechanisms, there may be a synergistic effect of the combination therapy. Therefore, a combination therapy may provide a faster resolution of severe skin lesions and consequently reduce the duration of the topical corticosteroid treatment. Another benefit of the combination therapy maybe the use of a lower potency corticosteroid to achieve the same degree of clearance. The hypothesis of this trial is that the combination of the two agents will lead to faster clearance than the single agent of topical corticosteroids.
NCT00119158 ↗ Combination Therapy for Atopic Dermatitis Completed Children's Hospital of Philadelphia Phase 4 2004-10-01 Atopic dermatitis is a chronic relapsing disease with acute flares. The standard therapy is to treat acute flares using topical medications. The two most common classes of topical medications for atopic dermatitis (AD) are topical corticosteroids and topical calcineurin inhibitors. Pimecrolimus and topical corticosteroids exert their activity by different mechanisms, there may be a synergistic effect of the combination therapy. Therefore, a combination therapy may provide a faster resolution of severe skin lesions and consequently reduce the duration of the topical corticosteroid treatment. Another benefit of the combination therapy maybe the use of a lower potency corticosteroid to achieve the same degree of clearance. The hypothesis of this trial is that the combination of the two agents will lead to faster clearance than the single agent of topical corticosteroids.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Elidel

Condition Name

Condition Name for Elidel
Intervention Trials
Atopic Dermatitis 23
Dermatitis, Atopic 4
Lupus Erythematosus, Cutaneous 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Elidel
Intervention Trials
Dermatitis 30
Eczema 28
Dermatitis, Atopic 28
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Elidel

Trials by Country

Trials by Country for Elidel
Location Trials
United States 164
Germany 15
Italy 4
United Kingdom 3
Canada 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Elidel
Location Trials
California 10
Florida 9
Texas 9
Virginia 9
North Carolina 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Elidel

Clinical Trial Phase

Clinical Trial Phase for Elidel
Clinical Trial Phase Trials
Phase 4 15
Phase 3 10
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Elidel
Clinical Trial Phase Trials
Completed 33
Terminated 3
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Elidel

Sponsor Name

Sponsor Name for Elidel
Sponsor Trials
Novartis 13
Novartis Pharmaceuticals 4
Astellas Pharma Inc 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Elidel
Sponsor Trials
Industry 34
Other 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Express Scripts
Colorcon
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.